HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $7
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $9 to $7.
HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $9 to $7.